Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study.

Gantenbein, Andreas R; Agosti, Reto; Gobbi, Claudio; Flügel, Dominique; Schankin, Christoph J.; Viceic, Dragana; Zecca, Chiara; Pohl, Heiko (2021). Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia, 41(11-12), pp. 1181-1186. Sage Publications 10.1177/03331024211014616

[img]
Preview
Text
Gantenbein__2021__Impact_on_monthly_migraine_days.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (447kB) | Preview

OBJECTIVE

This study aims to analyse the effect of the discontinuation of anti-calcitonin gene-related peptide antibodies on monthly migraine days after 12 treatment months.

BACKGROUND

Anti-calcitonin gene-related peptide antibodies have been a game changer in migraine prophylaxis. However, high treatment costs warrant reducing treatment duration to the essential minimum.

METHODS

We collected data of patients with migraine who had received anti-calcitonin gene-related peptide antibodies and had received treatment for 12 months.

RESULTS

We included 52 patients. The average number of monthly migraine days was 16 ± 7 days at baseline, 6 ± 6 in the third, and 5 ± 4 in the 12th treatment month. After treatment interruption, the number of monthly migraine days was 6 ± 4 days in the first month, 9 ± 4 days in the second, and 11 ± 5 days in the third month. Most patients (88.9%) restarted treatment.

CONCLUSION

Only little of the therapeutic effect of anti-calcitonin gene-related peptide antibodies outlasts their pharmacological effect. After treatment interruption, migraine frequency rose in most patients, and prophylaxis was required again in most cases.Limiting treatment to benefitting patients and confirming the need for prophylaxis periodically is reasonable. However, our data does not support the need for prescheduled treatment discontinuation after 12 months and a fixed duration of the treatment interruption of 3 months.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Schankin, Christoph Josef

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0333-1024

Publisher:

Sage Publications

Language:

English

Submitter:

Chantal Kottler

Date Deposited:

26 Jul 2021 14:50

Last Modified:

13 Nov 2021 06:04

Publisher DOI:

10.1177/03331024211014616

PubMed ID:

34000847

Uncontrolled Keywords:

Erenumab burden of disease galcanezumab treatment interruption

BORIS DOI:

10.48350/157653

URI:

https://boris.unibe.ch/id/eprint/157653

Actions (login required)

Edit item Edit item
Provide Feedback